
Jasper Therapeutics, Inc. (JSPR) Stock Ticker
JSPR right now
Market factors today
Unlock the full JSPR picture
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
JSPR stock facts
| Ticker symbol | JSPR |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $9.9M |
| CEO | Jeetinder Singh Mahal |
| Employees | 22 |
| Headquarters | Redwood City, CA, US |
| IPO date | 2020-01-10 |
| Website | jaspertx.com |
What you can see for JSPR on Tickr
Live JSPR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the JSPR report.
Rankings
FAQ
What is the ticker symbol for Jasper Therapeutics, Inc.?
The ticker symbol for Jasper Therapeutics, Inc. is JSPR, listed on the NASDAQ.
What is JSPR?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and…